shutterstock_1197728128_photobyphm-jpg
photobyphm / Shutterstock.com
13 August 2020Big PharmaMuireann Bolger

Bayer, Apotex settle suit over cancer drug patent

Bayer Healthcare Pharmaceuticals has settled a patent infringement suit with generics manufacturer  Apotex, after claiming that its version of a cancer treatment infringed two patents for cancer drug  Stivarga (regorafenib).

The suit was dismissed on August 4 but has yet to be approved by the  US District Court for the District of Delaware. No further details were provided.

In March 2017, Apotex notified Bayer that it was seeking approval from the Food and Drug Administration to create a generic version of Stivarga.

Later that same month, Bayer claimed that Apotex had infringed its patent, number 9,458,107, for the cancer drug and filed a suit at the Delaware court.

More than a year later, Bayer hit Apotex with another  patent suit relating to Stivarga at the same court in September 2018, this time for patent number 9,957,232. It filed a request for the blocking of generic copies until this patent expired in July 2032.

According to Bayer’s latest  quarterly earnings report, Stivarga generated sales of $295 million during the first half of 2020, up from $237 million during the same period in 2019.

Both companies have been approached for a comment.

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories like this sent straight to your inbox.


More on this story

Big Pharma
15 March 2019   Doctors’ handwriting poses a significant challenge to the registration of pharmaceutical trademarks, according to a senior counsel at German pharmaceutical company Bayer.
Americas
26 August 2020   Intercept Pharmaceuticals is suing Canadian generics manufacturer Apotex over a proposed version of autoimmune drug Ocaliva.
Americas
27 October 2020   Germany-based Bayer will pay up to $4 billion to acquire gene therapy company Asklepios BioPharmaceutical.

More on this story

Big Pharma
15 March 2019   Doctors’ handwriting poses a significant challenge to the registration of pharmaceutical trademarks, according to a senior counsel at German pharmaceutical company Bayer.
Americas
26 August 2020   Intercept Pharmaceuticals is suing Canadian generics manufacturer Apotex over a proposed version of autoimmune drug Ocaliva.
Americas
27 October 2020   Germany-based Bayer will pay up to $4 billion to acquire gene therapy company Asklepios BioPharmaceutical.